Company Updates

Artemis Resources Ltd (ASX: ARV) is pleased to announce the results of 33 km of Induced Polarisation (IP) surveys completed over a two month period at its Yandal Gold Project located on the Yandal Greenstone Belt in the Western Australian Goldfields region. The IP surveys have successfully defined anomalies within favourable greenstone host rocks and/or […]

Hannans Reward Ltd (Hannans) is pleased to report that the equal reduction of capital (the Restructure) as defined in the Notice of Annual General Meeting dated23 December 2012 and agreed to at the Annual General Meeting held on 31 January 2012 has been successfully completed. The Restructure has created a new unlisted public company, Errawarra […]

The Company has become aware of some misinformation regarding the terms of the Convertible Debenture (Agreement) entered into with Paladin Labs Inc. (Paladin), which was announced to the ASX on 16th January 2012. Specifically, the misinformation relates to the assets of the company that are encumbered under the debenture and could have been interpreted to, […]

Melbourne, Australia, 8 February 2012: Australian biopharmaceutical company Immuron Limited (ASX: IMC) has appointed Dr Stewart Washer as non-executive director. This appointment continues Immuron’s transformation to a commercially focused company. Dr Washer is currently the investment manager with IB Managers, a highly successful biotechnology fund in clinical stage Australian biotech companies. He is also a […]

A NOVEL TREATMENT that leaves a polyamide (PA) fabric flameretardant (FR) can simultaneously make the textile repellent to both oil and water, claims its developer, Alexium International Group of Perth, Australia. The FR part of the treatment works by applying a thin coating to the fabric that forms a nanocomposite char shield when exposed to […]

Melbourne, Australia, 31 January 2012: Australian biopharmaceutical company Immuron Limited (ASX:IMC), manufacturer of Travelan, has entered into a collaboration Agreement with Monash University to develop a product or products that will be aimed at both Prevention and treatment of Clostridium difficile (C difficile) infections. The therapeutic will be based on Immuron’s hyper-immune colostrums platform technology, […]

Oil Basins Limited (“OBL” or the “Company”; ASX codes “OBL”, “OBLOA” & “OBLOB”) is pleased to announce the successful placement of 50 million new ordinary OBL shares with „Sophisticated Investors‟ and „Professional Investors‟ at A$0.025 per share to raise $1,250,000. Subscribers to the placement include participation from Equity Underwriters Pty Ltd, Alpha Secuities Pty Ltd, […]

Natural compound specialists, BioProspect, has signed an agreement with Western Australian private biotech, Bio-Gene Technology, handing over exclusive worldwide rights to natural insecticide, Qcide. The deal involves four $200,000 fees paid annually to BioProspect and the University of Western Sydney as well as royalties of 4 per cent for the first $1 million in commercialisation […]

BIOPROSPECT has rejigged its licensing arrangement with unlisted Western Australian biotech company Bio-Gene for the Qcide natural insecticide, announcing it has agreed to assign the intellectual property to Bio-Gene for cash and an increased royalty share. Under the original deal between the two companies, announced in mid-2008, Bio-Gene paid BioProspect $100,000 up-front for the rights […]